Donepezil?+?chromone?+?melatonin hybrids as promising agents for Alzheimer's disease therapy.
Ontology highlight
ABSTRACT: We describe herein the design, multicomponent synthesis and biological studies of new donepezil?+?chromone?+?melatonin hybrids as potential agents for Alzheimer's disease (AD) therapy. We have identified compound 14n as promising multitarget small molecule showing strong BuChE inhibition (IC50?=?11.90?±?0.05?nM), moderate hAChE (IC50?=?1.73?±?0.34??M), hMAO A (IC50?=?2.78?±?0.12??M), and MAO B (IC50?=?21.29?±?3.85??M) inhibition, while keeping a strong antioxidant power (3.04 TE, ORAC test). Consequently, the results reported here support the development of new multitarget Donepezil?+?Chromone?+?Melatonin hybrids, such as compound 14n, as a potential drug for AD patients cure.
SUBMITTER: Pachon-Angona I
PROVIDER: S-EPMC6366423 | biostudies-literature | 2019 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA